NEOGENOMICS INC — Director's Dealing 2022

Mar 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2022-03-01

Reporting Person: Brown Douglas Matthew (Chief Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-01	Common Stock	A	35030	—	Acquired	77246	Direct
2022-03-02	Common Stock	F	867	—	Disposed	76379	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-01	Stock Option (Right to Buy)	$21.41	A	85519	Acquired	2029-03-01	Common Stock (85519.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$28.33	2027-03-02	Common Stock (45017.0)	45017	Direct
Stock Option (Right to Buy)	$53.17	2028-03-02	Common Stock (26378.0)	26378	Direct

Footnotes

F1: On March 1, 2022, Mr. Brown was granted 35,030 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.

F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2022 vesting of restricted stock.

F3: On March 2, 2020, Mr. Brown was granted 45,017 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F4: On March 2, 2021, Mr. Brown was granted 26,378 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 1, 2022, Mr. Brown was granted 85,519 stock options. These options vest ratably over the first four anniversary dates of the grant date.